Workflow
2024年9月第三周创新药周报
Southwest Securities·2024-09-25 08:03

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry as of September 22, 2024 [1]. Core Insights - The report highlights that the A-share innovative drug sector increased by 4.28% in the third week of September 2024, underperforming the CSI 300 index by 0.84 percentage points. The biopharmaceutical sector rose by 0.42% [12][13]. - In the Hong Kong market, the innovative drug sector rose by 2.38%, outperforming the Hang Seng Index by 2.81 percentage points [15]. - The XBI index in the US increased by 1.16%, with a cumulative increase of 9.1% over the past six months [17]. - The report notes that three new drugs were approved in China in September, with no new indications approved [18]. - The report also mentions significant sales growth for GLP-1 drugs, with Mounjaro achieving sales of $5.163 billion in 2023, a 970.1% increase [10]. Summary by Sections A-share and Hong Kong Market Performance - A total of 26 stocks in the innovative drug sector rose, while 34 stocks fell. The top gainers included Haichuang Pharmaceutical (+19.67%), Ascentage Pharma (+15.99%), and Genscript Biotech (+14.94%). The biggest losers were Rongchang Biopharma (-16.89%), Chuangsheng Group (-13.33%), and Shouyao Holdings (-11.78%) [12][13]. - Over the past six months, the A-share innovative drug sector has seen a cumulative decline of 3.33%, while the Hong Kong sector has increased by 4.99% [15]. Drug Approval and Clinical Trials - In September, three new drugs were approved in China, with no new indications. The report indicates that there were 21 new clinical trials announced, including 12 in Phase I, 5 in Phase II, and 4 in Phase III [18][27]. - In the US, one NDA was approved in the past week, with no new BLA approvals [20]. GLP-1 Drug Market Insights - The report details the progress of GLP-1 receptor agonists, noting that 11 drugs have been approved globally for diabetes, with three in NDA stage and nine in Phase III clinical trials [4]. - Sales figures for GLP-1 drugs show significant growth, with total sales for semaglutide products reaching $21.157 billion in 2023 [10].